Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa

Haematologica. 2005 Nov;90(11):1578-9.

Abstract

Eight patients with ocular adnexal mucosal-associated lymphpid tissue (MALT) lymphoma were treated with rituximab, at diagnosis (n=5) or relapse (n=3). All untreated patients achieved lymphoma regression, while relapsing patients had no benefit. Four responding patients experienced early relapse. The median time to progression was 5 months. The efficacy of rituximab in ocular adnexal lymphoma is lower than that reported for gastric MALT lymphomas.

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Eye Neoplasms / pathology
  • Eye Neoplasms / prevention & control
  • Eye Neoplasms / therapy*
  • Female
  • Humans
  • Lymphoma, B-Cell, Marginal Zone / drug therapy*
  • Lymphoma, B-Cell, Marginal Zone / pathology
  • Lymphoma, B-Cell, Marginal Zone / prevention & control
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / prevention & control
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab